Timothy C. Hain, MD Return to Index. Page last modified: March 6, 2016
Tuberculosis is presently a rare cause of ear infection in the United States. In the US, it is mainly managed by checking for positive TB skin tests, and then treating positive individuals. In other countries such as China, it is managed with vaccinations with BCG. Tuberculosis is much more common in immunocompromised individuals such as those with HIV infection. Most recent papers are from countries that have not managed to control their TB. TB disease is common in most countries in Latin America, the Caribbean, Africa, Asia, Eastern Europe, and Russia.
While tuberculosis is generally thought of as a lung disease, this is generally not true in persons with otic TB, where 83.3% are without lung disease (Rubio et al, 2015). TB can affect the middle ear and mastoid sinus, where it causes a discharge.
According to Rubio et al who reported a small number of cases (2015), the neuro-otologic manifestation was as follows: 85.7% sensorineural hearing loss; 42% polyneuropathy. 71.4% had granulation tissue. There are an immense number of other papers on otic TB, largely small case series.
The main method of detecting TB in the US is to look for a positive skin test. This does not work in individuals who have had BCG immunization however.
Pathological tests involve cultures (which take a long time to grow) or staining for acid-fast bacilli of secretions or biopsies.
There is also a blood test for tuberculosis called the "quantiferon TB gold". It detects both latent and active tuberculosis. It should be negative in persons vaccinated with BCG or infected with enviromental mycobacteria. It works by measuring the amount of interferon-gamma released from patient T-cells after stimulation with 3 mycobacterial proteins. A similar blood test is called the "T-spot".
Chest-X rays can be used to screen for TB, but of course it will not detect TB involving other organs such as the brain, spine or kidneys.
Otic TB is generally treated with the same medications as used for pulmonary TB (Kwon et al, 2010). Standard treatment includes isoniazide, rifampin, and other specialized medications (Bonfioli et al, 2005).